Analyzing the Sensitivity of EGFR-L861Q Mutation to TKIs and A Case Report
Background and objective The significant efficacy of tyrosine kinase inhibitors (TKIs) has been approved for advanced non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations. No clear evidence exists that EGFR-L861Q is sensitive to TKIs, and the...
Main Authors: | Xingxing WANG, Yutong DONG, Tingting LIANG, Xiongji ZHANG, Kewei MA, Yongsheng CUI |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2015-09-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2015.09.11 |
Similar Items
-
Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib
by: Vito Longo, et al.
Published: (2021-07-01) -
Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
by: Yu Saida, et al.
Published: (2019-11-01) -
The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations—The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations
by: Jiarong Tan, et al.
Published: (2021-08-01) -
Therapeutic Effect Of First-Line EGFR-TKIs Combined With Concurrent Cranial Radiotherapy On NSCLC Patients With EGFR Activating Mutation And Brain Metastasis: A Retrospective Study
by: An N, et al.
Published: (2019-10-01) -
Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
by: Kate S, et al.
Published: (2019-01-01)